BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of  59.1 nM for human TLR7.

TLR7 (human):59.1 nM (EC50)

BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 µg/mL)[1].

In an experimental study, mice that received only Chloroquine (CQ) for treatment showed signs of the parasite (P. berghei ANKA) by Day 17 and succumbed by Day 21. Conversely, those administered a combination of BBIQ and CQ did not exhibit any parasitic presence up to Day 23. Additionally, the combined treatment with BBIQ + CQ resulted in a reduction of T cell frequencies (CD3+, CD4+, and CD8+) and T regulatory cell frequencies (CD4+, CD25+, and FoxP3+) in the brain when compared to the effects of BBIQ or CQ alone on Day 10. This treatment also elevated the serum levels of IFN-γ and IL-12, indicating a strong Th1 immune response against the infection on the same day. The study suggests that the BBIQ + CQ combination therapy not only inhibits the infiltration of inflammatory T cells but also activates T helper and T cytotoxic cells to combat the parasite effectively.